Rabbit Anti-Human HTT Polyclonal antibody

Name: Rabbit Anti-Human HTT Polyclonal antibody
SKU: DPABH-05416
Rating: 5 (1 reviews)

Rabbit Anti-Human HTT Polyclonal antibody for WB, IHC, IF

Write a review

COA

SDS

Datasheet

Key features and details

Target: HTT
Host: Rabbit
Application: WB, IHC, IF
Species Reactivity: Human, Mouse, Rat

Summary

Specifications

Antibody Isotype

IgG

Species Reactivity

Human; Mouse; Rat

Immunogen

A synthetic peptide of human HTT.

Conjugate

Unconjugated

Applications

Application Notes

WB: 1:500-1:2000
IHC: 1:50-1:200
IF: 1:50-1:200

General Notes

This product (Catalog No. DPABH-05416) is a rabbit-derived polyclonal antibody raised against human HTT. This antibody exhibits cross-reactivity with HTT from mouse and rat. It has been affinity purified by Protein A. Huntingtin is a disease gene linked to Huntington's disease, a neurodegenerative disorder characterized by loss of striatal neurons. This is thought to be caused by an expanded, unstable trinucleotide repeat in the huntingtin gene, which translates as a polyglutamine repeat in the protein product. A fairly broad range of trinucleotide repeats (9-35) has been identified in normal controls, and repeat numbers in excess of 40 have been described as pathological. The huntingtin locus is large, spanning 180 kb and consisting of 67 exons. The huntingtin gene is widely expressed and is required for normal development. It is expressed as 2 alternatively polyadenylated forms displaying different relative abundance in various fetal and adult tissues. The larger transcript is approximately 13.7 kb and is expressed predominantly in adult and fetal brain whereas the smaller transcript of approximately 10.3 kb is more widely expressed. The genetic defect leading to Huntington's disease may not necessarily eliminate transcription, but may confer a new property on the mRNA or alter the function of the protein. One candidate is the huntingtin-associated protein-1, highly expressed in brain, which has increased affinity for huntingtin protein with expanded polyglutamine repeats. This gene contains an upstream open reading frame in the 5' UTR that inhibits expression of the huntingtin gene product through translational repression.
DPABH-05416 is suitable for use in Western blot (WB) (1:500–1:2,000), IHC (1:50–1:200), IF (immunofluorescence) (1:50–1:200) applications.
DPABH-05416 is supplied as a liquid formulation in PBS with 0.02% sodium azide, 50% glycerol, pH7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.

Target

Alternative Names

HD; IT15; HTT; Huntingtin

Entrez Gene ID

3064

UniProt ID

P42858

Citations

Have you cited DPABH-05416 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT

Authors: Keskin, Sonay; Brouwers, Cynthia C.; Sogorb-Gonzalez, Marina; Martier, Raygene; Depla, Josse A.; Valles, Astrid; van Deventer, Sander J.; Konstantinova, Pavlina; Evers, Melvin M.

Abstract

Huntington disease (HD) is a fatal neurodegenerative genetic disorder, thought to reflect a toxic gain of function in huntingtin (Htt) protein. Adeno-associated viral vector serotype 5 (AAV5)- microRNA targeting huntingtin (miHTT) is a HD gene-therapy candidate that efficiently lowers HTT using RNAi. This study analyzed the efficacy and potential for offtarget effects with AAV5-miHTT in neuronal and astrocyte cell cultures differentiated from induced pluripotent stem cells (iPSCs) from two individuals with HD (HD71 and HD180). One-time AAV5-miHTT treatment significantly reduced human HTT mRNA by 57% and Htt protein by 68% in neurons. Small RNA sequencing showed that mature miHTT was processed correctly without off-target passenger strand. No cellular microRNAs were dysregulated, indicating that endogenous RNAi machinery was unaffected by miHTT overexpression. qPCR validation of in silico-predicted off-target transcripts, next-generation sequencing, and pathway analysis confirmed absence of dysregulated genes due to sequence homology or seed-sequence activity of miHTT. Minor effects on gene expression were observed in both AAV5-miHTT and AAV5-GFP-treated samples, suggesting that they were due to viral transduction rather than miHTT. This study confirms the efficacy of AAV5-miHTT in HD patient iPSC-derived neuronal cultures and lack of off-target effects in gene expression and regulation in neuronal cells and astrocytes.

Identified handover tools and techniques in high-risk domains: Using distributed situation awareness theory to inform current practices

SAFETY SCIENCE

Authors: Clark, Jediah R.; Stanton, Neville A.; Revell, Kirsten M. A.

Abstract

In high-risk domains, poor shift handover has been identified as a key contributing factor in many incidents. This raises the question of: how can personnel collaborate effectively during shift changes? The vast majority of handover literature relates mainly to healthcare, aviation, energy generation and distribution domains. This review identified 19 distinct handover tools/techniques (HTTs) that domains employ to improve handover communication. The most prevalent HTT is standardisation in the form of a structured checklist, followed by the bidirectional exchange of information. This review assesses and summarises HTTs using 'distributed situation awareness' theory, and provides a comprehensive review on what is currently practised in high-risk domain handover, as well as a discussion around their potential contribution to raising distributed situation awareness.